Overview

Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias

Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare pembrolizumab to standard of care observation (no treatment) in controlling oral pre-malignant lesions and IENs. The safety and tolerability of pembrolizumab will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab